Novartis India's open offer to public shareholders closed with negligible participation. Only 40 shares were accepted, highlighting the shift in ownership was driven by a private sale from Novartis AG.
Novartis India Open Offer Closes With Minimal Shareholder Response
**Shares Tendered:** 182 **Shares Accepted:** 40 **Reader Takeaway:** Open offer closed with tiny public uptake; focus shifts to new promoters' strategy. ## What just happened Novartis India Ltd's mandatory open offer, a regulatory step following a majority stake acquisition, has concluded with very low participation from public shareholders. The offer aimed to acquire 64,19,608 shares at ₹860.64 per share. However, only 182 shares were tendered, and ultimately, just 40 shares were accepted. The total value of accepted shares amounted to ₹34,425.60. ## Why this matters The negligible response suggests that most public shareholders opted to retain their stake rather than sell at the offer price. The substantial change in ownership was primarily driven by the prior purchase of 70.68% of voting share capital from Novartis AG by WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. This event marks a formal completion of the change in control. ## The backstory The open offer was a procedural requirement stemming from the acquisition of a significant stake in Novartis India by WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. They purchased 1,74,50,680 equity shares, representing 70.68% of the company's voting share capital, from the former promoter, Novartis AG. ## What changes now With the closure of the open offer and the acquisition completed, the control of Novartis India will transition to the new group of acquirers. WaveRise Investments Limited and ChrysCapital Fund X will now be in control and become the new promoters, while Two Infinity Partners will be part of the promoter group. This signifies a change in the company's governance and strategic direction. ## Risks to watch Investors should be vigilant about potential changes in the company's operational focus and business strategy under the new management. Uncertainty regarding future corporate actions or restructuring could pose risks. ## Peer comparison While specific peer data for open offer participation is not directly comparable due to varied market conditions and offer structures, historically, mandatory open offers following large block deals can see mixed responses. However, such a low response rate as seen in Novartis India's case is exceptionally minimal. ## Context metrics (time-bound) The open offer period ran until June 24, 2026. The underlying acquisition from Novartis AG involved 1,74,50,680 equity shares, representing 70.68% of the voting share capital. The offer price was set at ₹860.64 per share. ## What to track next Shareholders should monitor future announcements from the company regarding strategic plans, operational changes, and any new management directives from the incoming promoter group. Understanding their long-term vision for Novartis India will be crucial.
Disclaimer:This article is published for informational purposes only. While reasonable efforts are made to ensure accuracy, completeness, and timeliness, readers are encouraged to independently verify information before making any decisions based on the content. The views and information presented are subject to editorial review and may be updated without notice.
